Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 8264830, 13 pages
http://dx.doi.org/10.1155/2016/8264830
Research Article

Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance

1Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan
2Department of Endocrinology, Diabetes and Geriatric Medicine, Akita University School of Medicine, 1-1-1 Hondo, Akita, Akita 010-8543, Japan
3Chugai Research Institute for Medical Science, 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan
4Project Planning & Coordination Department, Chugai Pharmaceutical Co., Ltd., 2-1-1 Nihonbashi, Muromachi, Chuo-ku, Tokyo 103-8324, Japan

Received 16 June 2015; Revised 26 September 2015; Accepted 29 September 2015

Academic Editor: Raffaella Mastrocola

Copyright © 2016 Atsunori Ueyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Nagata, M. Fukazawa, K. Honda et al., “Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats,” American Journal of Physiology—Endocrinology and Metabolism, vol. 304, no. 4, pp. E414–E423, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Ohtake, T. Sato, T. Kobayashi et al., “Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes,” Journal of Medicinal Chemistry, vol. 55, no. 17, pp. 7828–7840, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Tilg and A. R. Moschen, “Insulin resistance, inflammation, and non-alcoholic fatty liver disease,” Trends in Endocrinology and Metabolism, vol. 19, no. 10, pp. 371–379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Siddle, “Signalling by insulin and IGF receptors: supporting acts and new players,” Journal of Molecular Endocrinology, vol. 47, no. 1, pp. R1–R10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Cusi, K. Maezono, A. Osman et al., “Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle,” The Journal of Clinical Investigation, vol. 105, no. 3, pp. 311–320, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Crews, A. Alessandrini, and R. L. Erikson, “The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product,” Science, vol. 258, no. 5081, pp. 478–480, 1992. View at Publisher · View at Google Scholar · View at Scopus
  7. D. R. Alessi, Y. Saito, D. G. Campbell et al., “Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1,” The EMBO Journal, vol. 13, no. 7, pp. 1610–1619, 1994. View at Google Scholar · View at Scopus
  8. A. Dunaif, J. Xia, C.-B. Book, E. Schenker, and Z. Tang, “Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome,” Journal of Clinical Investigation, vol. 96, no. 2, pp. 801–810, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Krook, M. Björnholm, D. Galuska et al., “Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients,” Diabetes, vol. 49, no. 2, pp. 284–292, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. A. A. Osman, M. Pendergrass, J. Koval et al., “Regulation of MAP kinase pathway activity in vivo in human skeletal muscle,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 278, no. 6, pp. E992–E999, 2000. View at Google Scholar · View at Scopus
  11. M. Fujishiro, Y. Gotoh, H. Katagiri et al., “Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes,” Molecular Endocrinology, vol. 17, no. 3, pp. 487–497, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Izawa, M. Yoshizumi, Y. Fujita et al., “ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells,” Experimental Cell Research, vol. 308, no. 2, pp. 291–299, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Imai, H. Katagiri, T. Yamada et al., “Regulation of pancreatic beta cell mass by neuronal signals from the liver,” Science, vol. 322, no. 5905, pp. 1250–1254, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Pagès, S. Guérin, D. Grall et al., “Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice,” Science, vol. 286, no. 5443, pp. 1374–1377, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Mazzucchelli, C. Vantaggiato, A. Ciamei et al., “Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory,” Neuron, vol. 34, no. 5, pp. 807–820, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Bost, M. Aouadi, L. Caron et al., “The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis,” Diabetes, vol. 54, no. 2, pp. 402–411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. J. C. Selcher, T. Nekrasova, R. Paylor, G. E. Landreth, and J. D. Sweatt, “Mice lacking the ERK1 isoform of MAP kinase are unimpaired in emotional learning,” Learning and Memory, vol. 8, no. 1, pp. 11–19, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Giroux, M. Tremblay, D. Bernard et al., “Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta,” Current Biology, vol. 9, no. 7, pp. 369–372, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Yao, W. Li, J. Wu et al., “Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 22, pp. 12759–12764, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. K. Saba-El-Leil, F. D. J. Vella, B. Vernay et al., “An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development,” EMBO Reports, vol. 4, no. 10, pp. 964–968, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Hatano, Y. Mori, M. Oh-hora et al., “Essential role for ERK2 mitogen-activated protein kinase in placental development,” Genes to Cells, vol. 8, no. 11, pp. 847–856, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Lee, H. Niu, R. Rueger et al., “The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker,” Clinical Cancer Research, vol. 15, no. 23, pp. 7368–7374, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Zimmer, F. Barlesi, M. Martinez-Garcia et al., “Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations,” Clinical Cancer Research, vol. 20, no. 16, pp. 4251–4261, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Ishii, N. Harada, E. W. Joseph et al., “Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity,” Cancer Research, vol. 73, no. 13, pp. 4050–4060, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Aoki, I. Hyohdoh, N. Furuichi et al., “The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 23, pp. 6223–6227, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Martinez-Garcia, U. Banerji, J. Albanell et al., “First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors,” Clinical Cancer Research, vol. 18, no. 17, pp. 4806–4819, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Honda, N. Yamamoto, H. Nokihara et al., “Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors,” Cancer Chemotherapy and Pharmacology, vol. 72, no. 3, pp. 577–584, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Isshiki, Y. Kohchi, H. Iikura et al., “Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 6, pp. 1795–1801, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. S. M. Furler, G. S. Zelenka, and E. W. Kraegen, “Development and testing of a simple algorithm for a glucose clamp,” Medical and Biological Engineering and Computing, vol. 24, no. 4, pp. 365–370, 1986. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Rogatsky, H. Jayatillake, G. Goswami, V. Tomuta, and D. Stein, “Sensitive LC MS quantitative analysis of carbohydrates by Cs+ attachment,” Journal of the American Society for Mass Spectrometry, vol. 16, no. 11, pp. 1805–1811, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Bergeron, S. F. Previs, G. W. Cline et al., “Effect of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese zucker rats,” Diabetes, vol. 50, no. 5, pp. 1076–1082, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Ban, Y. Yamada, Y. Someya et al., “Activating transcripton factor-2 is a positive regulator in CaM kinase IV-induced human insulin gene expression,” Diabetes, vol. 49, no. 7, pp. 1142–1148, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Ban, Y. Yamada, Y. Someya et al., “Hepatocyte nuclear factor-1alpha recruits the transcriptional co-activator p300 on the GLUT2 gene promoter,” Diabetes, vol. 51, no. 5, pp. 1409–1418, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. U. K. Laemmli, “Cleavage of structural proteins during the assembly of the head of bacteriophage T4,” Nature, vol. 227, no. 5259, pp. 680–685, 1970. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Nakamura and K. Yamada, “Studies on a diabetic (KK) strain of the mouse,” Diabetologia, vol. 3, no. 2, pp. 212–221, 1967. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Furuno, K. Shimakawa, and Z. Suzuoki, “Effects of nutritional factors on the development of ethanol induced fatty liver in KK and KK-Ay mice,” Journal of Nutrition, vol. 105, no. 10, pp. 1263–1268, 1975. View at Google Scholar · View at Scopus
  37. J. C. Mavropoulos and T. S. Wang, “Managing the skin toxicities from new melanoma drugs,” Current Treatment Options in Oncology, vol. 15, no. 2, pp. 281–301, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Zhao and A. A. Adjei, “The clinical development of MEK inhibitors,” Nature Reviews Clinical Oncology, vol. 11, no. 7, pp. 385–400, 2014. View at Publisher · View at Google Scholar · View at Scopus